18 and older, any sex, with Psoriasis or Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Proportion of Participants Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16Primary· Week 16
The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale) and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and con
Group
Value
95% CI
Placebo Q2W (RS)
11.6
CZP 200 mg Q2W (RS)
81.4
CZP 400 mg Q2W (RS)
82.6
Proportion of Participants Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 16Primary· Week 16
The Investigator assessed the overall severity of Psoriasis (PSO) using the following 5-point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.
Group
Value
95% CI
Placebo Q2W (RS)
2.0
CZP 200 mg Q2W (RS)
66.8
CZP 400 mg Q2W (RS)
71.6
Proportion of Participants Who Achieve a Psoriasis Activity and Severity Index (PASI90) Response at Week 16Secondary· Week 16
The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale) and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and con
Group
Value
95% CI
Placebo Q2W (RS)
4.5
CZP 200 mg Q2W (RS)
52.6
CZP 400 mg Q2W (RS)
55.4
Proportion of Participants Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 48Secondary· Week 48
The Investigator assessed the overall severity of Psoriasis (PSO) using the following 5-point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.
Group
Value
95% CI
CZP 200 mg Q2W (RS)
72.6
61.22 – 83.92
CZP 400 mg Q2W (RS)
66.6
54.35 – 78.86
Proportion of Participants Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 48Secondary· Week 48
The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale) and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and con
Group
Value
95% CI
CZP 200 mg Q2W (RS)
78.7
68.93 – 88.45
CZP 400 mg Q2W (RS)
81.3
71.90 – 90.67
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16Secondary· Week 16
The DLQI is a subject-reported questionnaire designed for use in adult subjects with PSO. The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL). This instrument asks subjects about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. It has been shown to be valid and reproducible in PSO patients. The DLQI score ranges from 0 to 30 with higher scores indicating lower HRQoL. A higher than or equal to (\>=) 4-point change in the DLQI score
Group
Value
95% CI
Placebo Q2W (RS)
-3.8
± 0.84
CZP 200 mg Q2W (RS)
-10.4
± 0.62
CZP 400 mg Q2W (RS)
-10.0
± 0.64
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse Events (AEs) were collected from Baseline (Week 0) until the Post Study Safety Follow-up Visit (Week 152)..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07491913 — Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
· NA
· recruiting
NCT03100253 — Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
· Phase 4
· terminated
NCT03051217 — A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psori
· Phase 2, PHASE3
· completed
NCT03020992 — A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloar
· Phase 4
· completed
NCT02346240 — Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psori
· Phase 3
· completed
Other recruiting trials for Psoriasis
Currently open trials in the same condition.
NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria
· NA
· recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
· recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
· recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial
· Phase 2
· recruiting
NCT07250997 — PALLAS Laser for Skin Diseases
· NA
· recruiting
Other UCB Biopharma S.P.R.L. trials
Trials by the same sponsor.
NCT04136444 — A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
· Phase 1
· terminated
NCT04126343 — A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants
· Phase 1
· terminated
NCT04075409 — A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants
· Phase 1
· completed
NCT04039919 — A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participan
· Phase 1
· terminated
NCT04013191 — A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Partic
· Phase 1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UCB Biopharma S.P.R.L.
Last refreshed: 3 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02326272.